After a double mastectomy, followed by chemotherapy, Hannah was confident that she'd beaten cancer. Even when cancer was ...

The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for avutometinib to be used in combination with defactinib for the treatment of adults with ...

GT-201 is under clinical development by Shanghai Grit Biotechnology and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.

Onvapegleukin alfa is under clinical development by Ascendis Pharma and currently in Phase II for Ovarian Cancer.

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

Verastem's promising therapy for LGSOC could position them as a commercial-stage company by 2025. Click here to find out why ...

The Minnesota Department of Health (MDH) says about 3,850 women in Minnesota are living with an ovarian cancer diagnosis and ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...

FDA officials have set a review date of June 30, 2025, to review avutometinib in combination with defactinib to treat ...

The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%.

Experts say ovarian cancer causes more deaths than all other female reproduction system cancers and is difficult to diagnose ...